Clinical significance of hepatitis B surface antigen mutants

Nicola Coppola, Lorenzo Onorato, Carmine Minichini, Giovanni Di Caprio, Mario Starace, Caterina Sagnelli, Evangelista Sagnelli

Caterina Sagnelli, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, 80131 Naples, Italy

Author contributions: Coppola N has contributed to conception of the paper and draft the article; Onorato L has analyzed the role of HBsAg mutants associated with HCC development; Minichini C has analyzed the HBV virology and HBsAg structure; Di Caprio G has analyzed the role of HBsAg mutants associated with immune escape; Starace M has analyzed the HBV virology and HBsAg structure; Sagnelli C has analyzed the role of HBsAg mutants associated with failed HBsAg detection; Sagnelli E has contributed to conception of the paper and draft the article.

Conflict-of-interest statement: The authors declare no conflicts of interest regarding this manuscript.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Nicola Coppola, MD, PhD, Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Via: L. Armanni 5, 80131 Naples, Italy. nicola.coppola@unina2.it
Telephone: +39-8-15666719
Fax: +39-8-15666013

Received: June 30, 2015
Peer-review started: June 30, 2015
First decision: September 18, 2015
Revised: September 27, 2015
Accepted: November 13, 2015
Article in press: November 17, 2015

Published online: November 28, 2015

Abstract

Hepatitis B virus (HBV) infection is a major public health problem in many countries, with nearly 300 million people worldwide carrying HBV chronic infection and over 1 million deaths per year due to cirrhosis and liver cancer. Several hepatitis B surface antigen (HBsAg) mutations have been described, most frequently due to a single amino acid substitution and seldom to a nucleotide deletion. The majority of mutations are located in the S region, but they have also been found in the pre-S1 and pre-S2 regions. Single amino acid substitutions in the major hydrophilic region of HBsAg, called the “a” determinant, have been associated with immune escape and the consequent failure of HBV vaccination and HBsAg detection, whereas deletions in the pre-S1 or pre-S2 regions have been associated with the development of hepatocellular carcinoma. This review article will focus on the HBsAg mutants and their biological and clinical implications.

Key words: Hepatitis B virus infection; Vaccine escape; Immune escape hepatocellular carcinoma; Hepatitis B surface antigen mutants

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Antibodies to the hepatitis B surface antigen (HBsAg) produced in response to hepatitis B virus infection or vaccination and those used in diagnostic assays to detect this antigen in serum are both directed against the “a” determinant region, common to all subtypes of the virus. Mutations occurring on the loops of the “a” determinant may be responsible for the lack of protection in immunized patients and in those individuals receiving hepatitis B immune globulin or for failed detection of HBsAg using commercial diagnostic tests.

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
assays. There is growing evidence in the last decade of the association between HBsAg mutations and the development of hepatocellular carcinoma (HCC), suggesting that the pre-S1 or pre-S2 large deletions are those prevalent associated with the development of HCC. This review article will focus on the clinical impact of the various HBsAg mutants.

Coppola N, Onorato L, Minichini C, Di Caprio G, Starace M, Sagnelli C, Sagnelli E. Clinical significance of hepatitis B surface antigen mutants. World J Hepatol 2015; 7(27): 2729-2739
Available from: URL: http://www.wjgnet.com/1948-5182/full/v7/i27/2729.htm DOI: http://dx.doi.org/10.4254/wjh.v7.i27.2729

INTRODUCTION

Hepatitis B virus (HBV) infection is a major public health problem in most countries, with approximately 2 billion people worldwide showing exposure to the virus, nearly 300 million carrying HBV chronic infection and over 1 million deaths per year due to HBV-related end-stage liver disease, liver cirrhosis and liver cancer.[1-3]

HBV is an enveloped Hepadnavirus with an incomplete double-stranded DNA genome of 3.2 Kb.[4] Eight genotypes, with a distinct geographical distribution, have been identified to date. Genotype A prevails in northwestern Europe and in the United States, genotypes B and C in Asia, genotype D in the Mediterranean basin, the Middle East, and India, genotype E in Western Africa, genotype F in South and Central America, genotype G in the United States and France, genotype H in Northern Latin America,[5] genotype I in Laos, Vietnam, Eastern India[6] and North-Western China[7] and genotype J in Japan.[8,9]

The worldwide prevalence of chronic HBV infection in the general population borders 5%, but it differs widely from one geographical area to another, from 0.1%-2.0% in the United States and Western Europe, from 2.0%-8.0% in Eastern Mediterranean countries and Japan, and from 5.0%-20.0% in South-Eastern Asia and sub-Saharan Africa.[10,11]

Risk factors for HBV infection include transfusion of unscreened blood, renal dialysis, sexual promiscuity, sharing or re-using syringes among injection drug users, tattooing, piercing, working or residing in a healthcare setting, living in a correctional facility and long-term household or intimate non-sexual contact with an HBsAg-positive individual. In highly endemic areas the majority of hepatitis B surface antigen (HBsAg) chronic carriers acquire HBV infection at birth or in the first decade of life, whereas in countries with a low endemicity HBV transmission occurs mostly in adulthood due to unprotected sexual contact, syringe sharing or parenteral exposure to contaminated medical equipment.[12-17]

A vaccine against HBV became available in 1982, and ten years later the World Health Organization recommended universal vaccination of newborn babies with the HBsAg produced by yeast cells into which the genetic code for HBsAg had been inserted. The complete vaccination schedule induces protective antibody levels in more than 95% of infants, children and young adults.

The emergence of single or multiple amino acid substitutions in the HBsAg region has been found in infants born to HBsAg-positive mothers who underwent passive/active immunoprophylaxis at the birth, in HBsAg-positive liver transplant recipients treated with hyperimmune anti-HBs immune globulin and in patients who experienced loss of HBsAg after anti-HBV therapy.

This review article focuses on the impact of HBsAg mutants on vaccine escape, failure of diagnostic tests to detect HBsAg, and on the development of hepatocellular carcinoma (HCC).

HBV VIROLOGY

Human HBV is the prototype member of the Hepadnaviridae family, which includes a variety of avian and mammalian viruses sharing similar genomic organization, organ tropisms and a unique strategy of genome replication.[14]

HBV is one of the smallest enveloped animal viruses with a diameter of 42 nmol/L consisting of an outer lipid envelope and an icosahedral nucleocapsid core composed of proteins. The nucleocapsid encloses the viral DNA and a DNA polymerase acting also as a reverse transcriptase[17]. The outer envelope contains the embedded proteins HBsAg, pre-S1 and pre-S2 involved in the viral binding of, and entry into susceptible cells. HBV is also called “Dane particle” after the name of the researcher who first observed it on electron microscopy together with filaments and 22 nmol/L spherical bodies in the serum of infected individuals[18]. HBV infects the hepatocytes, whereas the filaments and spherical bodies do not contain the viral DNA and do not infect the liver cells. These filaments and spherical bodies show the same HBsAg reactivity as the surface of HBV and are considered to be produced by HBsAg in excess during the life cycle of the virus[19].

The HBV genome consists of 3200 base pairs of partially double-stranded circular DNA containing four (P, C, S and X) overlapping open reading frames (ORF) with a nucleotide diversity of ≥ 8% in different genotypes.[15,16]. The P gene codes for the viral polymerase/reverse transcriptase. It has four domains: A terminal domain, which serves as a protein primer for reverse transcription of pre-genomic viral RNA, a spacer region without no apparent function, the polymerase domain, which has reverse transcription activity, and the RNase H domain, responsible for the degradation of the RNA template during reverse transcription.

The core (C) gene codes for HBCAg, the major structural protein of the nucleocapsid. The preC/C ORF is transcribed into a precore/core fusion protein. During entry into the endoplasmic reticulum, 19 amino acids are cleaved from the N-terminal end of the precore protein by a signal peptidase. When transported into the
Golgi compartment, additional amino acids are removed from the C-terminal end by intra-Golgi proteases to form the HBe antigen. This antigen, which is secreted into the serum, is used as a marker of active HBV replication in clinical practice. The possibility that the circulating HBe antigen may suppress the immune response and favor HBV replication has been hypothesized but never proven, and the biological function of this protein, if any, remains unknown. The preS/S ORF encodes the envelope proteins HBsAg, pre-S1 and pre-S2. The X gene codes for potent transactivating factors of viral and cellular genes (HBxAg), some of which possibly correlated to the development of HCC.

HBSAg structure and variants
The preS/S ORF encodes three different structurally related envelope proteins, termed the large (L), middle-sized (M) and small (S) protein, that is synthesized from alternative initiation codons. The three proteins share the same carboxy-terminus but have different amino terminal extensions. In particular, the S protein corresponding to the HBsAg consists of 226 amino acids (aa), the M protein contains an extra N-terminal extension of 55 aa, and the L protein has a further N-terminal sequence of 108-119 aa compared with the M protein. The enhancer and basic core promoter regions of S region overlap with the X gene.

HBsAg is an envelope glycoprotein that is currently the primary element for diagnosis and target of immunoprophylaxis of HBV infection. The dominant epitopes of HBsAg, which are the targets of neutralizing B-cell responses, reside in the “a” determinant (aa 124-147) within the major hydrophilic region (MHR).

Several mutations in the S region have been described and those most frequently reported in the literature are listed in Table 1. In most cases, they were aa substitutions due to a single mutation, but nucleotide deletions have also been reported. The majority of mutations were located in the S region, but some mutations were also identified in the pre-S1 or pre-S2 regions. Mutations in the S region have been found in various HBV genotypes, while those in pre-S1 or pre-S2 have been frequently observed in patients with HBV genotype C (Table 1).

Clinical significance of HBsAg
Mutants
Some HBsAg mutants have been associated with major biological or clinical events such as immune escape, failure to detect HBsAg and the development of HCC.

HBsAg mutants associated with immune escape
The MHR region, which is exposed to the outer surface of the virion, is situated between aa 99-169 of HBsAg. The antibodies produced after HBV vaccination and those used in diagnostic assays to detect serum HBsAg are both directed against this region and, specifically, to a cluster of B-cell epitopes, common to all subtypes of the virus, called “a” determinant and showing a two-loop structure of aa (124-147). Mutations may occur on both loops of the “a” determinant and may be responsible for a lack of protection and the occurrence of HBV infection in immunized patients (vaccine escape) or for failure to protect by the HBIG administered as a prophylactic measure or failure to detect HBsAg in diagnostic assays. Table 2 lists the studies suggesting the association of HBsAg mutants with vaccine escape or failed HBsAg detection.

In 1988 a follow-up Italian study reported that children with a strong antibody response to HBV vaccine may still become infected with HBV. This observation was confirmed in other investigations and the conclusion on this point is that this phenomenon may involve nearly 2% of children born of HBsAg-positive mothers or with other HBsAg-positive household contacts. More detailed analysis identified an association of vaccine escape with a point mutation from glycine to arginine at position 145 (G145R). This G145R mutation is the vaccine-escape mutant most frequently detected stable over time and horizontally transmissible.

Mismatches in the HBV S gene differed: One infant harbored three nucleic acid changes (P120Q, F134Y and D144A) and the other was carrying the I126N substitution, three nucleic acid changes (P120Q, F134Y and D144A) and the other was carrying the I126N substitution, mutations that may interfere with HBsAg/anti-HBs binding. Mismatches in the HBV S gene were also observed in 16 of 41 HBV-infected mother/infant pairs in Singapore, of whom the infants acquired HBV infection despite HBV passive/active immunization.

HBsAg mutants associated with failed HBsAg detection
In 1999, Coleman et al. demonstrated that three commercial assays did not detect serum HBsAg in patients showing mutations including G145R in the “a” determinant. Subsequently, Zhang et al. prepared a panel containing four dilutions of an HBsAg wild-type serum, three recombinant mutants (G145R, K141E, and T131I) and one negative sample. This panel was tested for HBsAg reactivity by the laboratories of 85 blood banks using different assays. HBsAg reactivity was detected only in 19.4% of the assays in the presence of the aa substitution G145R and in 20% in the presence of the T131I or K141E mutants.

Sticchi et al. found G145A HBsAg mutants in 8 (3.1%) of 256 HBsAg chronic carriers, alone in 5 and with other HBsAg mutations in 3 (T126I, T131A, and...
Table 1  Mutations reported in the hepatitis B surface antigen regions

| Codon | Type mutation | Mutation | Phenotypic consequence | HBV genotype | Ref. |
|-------|---------------|----------|------------------------|--------------|------|
| Wt\'t agt, Mt\'t acg, Wt\'t\' tac, Mt\'t tgc, Mt\'t cac, Wt\'t tt, Mt\'t tgg | AAS | M197T, Y200C/H1, F220L | Low serum HBV DNA | D | [23] |
| Wt\'t gga | AAS | G145A | Immune escape\(^1\) | A-B-C-D | [24,34,47] |
| Mt\'t gca | AAS | G145R | Immune escape\(^1\) | A-B-C-D | [28,35,36,40,41,45,47-50] |
| Wt tgc | AAS | C121W | Immune escape | A | [25] |
| Mt tgg | AAS | C147W | Immune escape | D | [25,26] |
| Wt tgc, Mt tgg | AAS | C147W | Immune escape | D | [25,26] |
| Wt act, Mt att | AAS | T189I | Immune escape, reducing HBsAg detection signal | E-A | [27,28,33] |
| Wt act, Mt aat | AAS | I126N | Immune escape | C | [29] |
| Wt cAa, Mt cga | AAS | Q129R | Vaccine escape | B | [30,34] |
| Wt ttc, Mt tac | AAS | F161Y | Immune escape | C | [31,51] |
| Wt atg, Mt atc | AAS | M103I | Immune escape | D | [24,52] |
| Wt ttc, Mt tgc | AAS | L94S | HCC | D | [32] |
| Wt gac, Mt gaa | AAS | D144E | Immune escape | D, C, A | [28,33,40,52] |
| Wt cct, Mt Tct | AAS | P127S | Immune escape | B, D | [33,34,39] |
| Wt act, Mt agt | AAS | T126S | Immune escape | B | [33,34,38] |
| Wt act, Mt act | AAS | T126I | Immune escape | C, D | [28,34,53] |
| Wt act, Mt acg | AAS | T143S | Immune escape | C, A | [34,53] |
| Wt cca, Mt cca | AAS | P120T | Immune escape | B, D | [34,53] |
| Wt gca, Mt gca | AAS | Y134F | Immune escape | E | [27] |
| Wt gta, Mt gca | AAS | V184A | Immune escape | E | [27] |
| Wt Tcg, Mt acg | AAS | S143T | Immune escape | E | [25,27,53] |
| Wt tgt, Mt ttc | AAS | C76F | Immune escape | E | [27] |
| Wt cct, Mt act | AAS | P70T | Immune escape | E | [27] |
| Wt atc, Mt act | AAS | I82T | Immune escape | E | [27] |
| Wt att, Mt att | AAS | T126L | Immune escape | A, C | [25,53] |
| Wt tat, Mt tt | AAS | Y134F | Immune escape | D | [25,55] |
| Wt agt, Mt acc | AAS | S207N | Immune escape | D | [25,56] |
| Wt tat, Mt cat | AAS | Y134H | Immune escape | D | [52] |
| Wt acg, Mt aat | AAS | T125N | Increased HBsAg reactivity in immunological diagnostic assays | D | [43] |
| Wt atg, Mt atc, WT aag, Mt agg | AAS | M103I-K122R | Immune escape | A-C-D | [24] |
| Wt tat, Mt tgt | AAS | Y100C | Immune escape | B-C | [45] |
| Wt ccc, Mt ctc, MtQ cca, MtS tgt, MtT cta | AAS | P120L/Q/S/T | Immune escape | B-C | [45] |
| Wt cgg, Mt cgg | AAS | S143L | Immune escape | D | [52] |
| Wt ctt, Mt ctt | AAS | L127P | Immune escape | E | [27] |
| Wt ctt, Mt ctt | AAS | P127L | Immune escape | A | [27] |
| Mutations in pre-S1 region | | | | | |
| Wt tct, Mt tca | AAS | S98T | Significant association with disease progression (LF, LC, HCC) | D | [57] |
| Wt aac, Mt act | AAS | N48T | Reduced HBsAg detection signals | C | [27] |
| Wt cag, Mt cct | AAS | Q82P | Reduced HBsAg detection signals | C | [27] |
| Wt acc, Mt aat | AAS | T97N | HBsAg not detected | C | [27] |
| Wt aat, Mt acc | AAS | N97T | HBsAg not detected | E | [27] |
| Wt cct, Mt cag | AAS | P93Q | HBsAg not detected | E, C | [27] |
| Deletion size (bp) 39 | D | Region (nt) 3046-3084 | Progression to advanced liver disease | C | [58] |
| Deletion size (bp) 108 | D | Region (nt) 3095-3096 | Progression to advanced liver disease | C | [58] |
| Deletion size (bp) 39 | D | Region (nt) 3046-3084 | Progression to advanced liver disease | C | [58] |
| Deletion size (bp) 108 | D | Region 2959-3066 | Progression to advanced liver disease | C | [58] |
| 104<sup>d</sup> codon | AAS | Q104Stop | HCC development and immune escape | C | [59] |
| preS1 start | D | Not specified | HCC development and immune escape | C | [59] |
| Wt ucc, Mt gcc | AAS | S17A | Immune escape | C | [59] |
| Wt cct, Mt ctt | AAS | P52L | Immune escape | C | [59] |
| Wt tgg, Mt tgt, Mt agg | AAS | W42L/R | Immune escape | C | [59] |
| 104<sup>d</sup> codon | AAS | Q104Stop | HCC development and immune escape | C | [59] |
| Mutations in pre-S2 region | | | | | |
| Not specified | AAS | preS2-W35Stop | Immune escape | C | [59] |
| From 8th codon to 23<sup>e</sup> codon | D | | Immune escape | C | [59] |

AAS: Amino acid substitution; D: Deletion; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HBsAg: Hepatitis B surface antigen; LC: Liver cirrhosis; LF: Liver fibrosis.
C139Y, E/D144G, T126I, M133L, P120Q or T126I). In the three patients with a multiple mutation, HBsAg was undetectable by 3 of 5 routine assays used in this study.

HBsAg mutants associated with failure to detect HBsAg have also been observed in patients with acute hepatitis B. Laoi et al. [78] studied 32 consecutive patients with acute hepatitis B and found a single or multiple amino acid substitution in 6 (18.5%) isolates. The G145A substitution along with the F134L were responsible for failure to detect HBsAg in one of these 6 and the D144E and S143L in another two isolates, whereas the other mutants identified (R113Thr, Ser114-Pro, Thr118Val, Ala128Val) were of unclear significance.

**HBsAg mutations associated with HCC development**

The HBsAg mutations prevalently associated with the development of HCC are the large deletions involving the pre-S1 or pre-S2 regions. These deletions naturally occur during the chronic phase of HBV infection and induce the synthesis of truncated variants of the large envelope protein, with important immunological and clinical consequences. In fact, these variants present reduced antigenicity and, by altering the immune response, may favour the replicative activity of the virus. In addition, the pre-S deletions decrease the expression of middle and small surface proteins, resulting in intracellular accumulation of viral particles that may induce stress in the endoplasmic reticulum, oxidative DNA damage and genomic instability, and possibly lead to a higher rate of neoplastic transformation. The growing evidence on the association between HBsAg mutations and the development of HCC emerging in the last decade is shown in Table 3.

In 2003, Huy et al. [83] conducted a multicenter cross-sectional study on 352 HBsAg-positive patients from 12 countries in five continents or subcontinents and demonstrated a higher prevalence of pre-S1 and/or pre-S2 deletions and pre-S2 start codon mutations in patients with HCC than in those without (35.7% vs 16.5%, \( P < 0.05 \)). In accordance with this, a correlation between a pre-S deletion and the presence of liver cirrhosis or HCC was described in an observational Japanese study [86]. Also, in a cross-sectional Italian study, the prevalence of pre-S2 deletions or start codon mutations was much higher in the 19 patients with HBV-related HCC than in 91 HBV carriers without HCC (84.2% vs 43.9%, \( P < 0.02 \)) [87]. In 2006, Chen et al. [88] found a higher prevalence of pre-S deletions in 50 Taiwanese patients with HBV-related hepatocellular carcinoma than in 102 HBV-infected individuals without HCC (52.0% vs 29.4%, \( P < 0.001 \)). Similar data come from three studies performed in Taiwan [89], South Korea [90] and China [91], respectively. In addition, a South Korean study performed by Mun et al. [92] demonstrated a correlation of both pre-S1 deletions and pre-S1 start codon mutations with the occurrence of HCC (\( P = 0.027 \) and \( P = 0.048 \), respectively); in this study the presence of pre-S2 deletions was also significantly associated with the development of liver cirrhosis (\( P = 0.001 \)). The association of pre-S deletions and pre-S2 start codon mutations with the presence or the development of HCC was confirmed in other studies performed in southern Asia [93-95]. Moreover, a cross-sectional South Korean study on 119 HBsAg-positive patients showed a higher prevalence of pre-S1 deletions in patients with HCC than in those without. In a case-control study on 192 HBsAg-positive patients from Taiwan, the pre-S2, but not pre-S1 deletions, were associated with the occurrence of HCC, data endorsed by the results of a subsequent South Korean case-control study on 270 HBV-infected patients that described a correlation between pre-S2 but not pre-S1 deletions or pre-S2 start codon mutations and HCC. The pre-S deletions were significantly associated with the development of HCC also in a study performed by Kao et al. on 168 HBV chronic patients from Taiwan.

A prospective study performed in South Korea investigated 195 patients with chronic HBV infection and showed a higher incidence of HCC in those who

| Ref. | Country       | No. of patients | Type of study | Patients with HBsAg mutation, \( n \) (%) | Clinical significance | HBsAg mutation |
|------|--------------|----------------|---------------|------------------------------------------|-----------------------|----------------|
| Sticchi et al. [86] | Italy | 256 | Cross-sectional | 8 (3.1) | Detection failure; vaccine escape | G145R, T126I |
| Luongo et al. [78] | Italy | 1 | Case report | 1 | Vaccine escape | M125T, T127P, Q129H |
| Lee et al. [79] | South Korea | 1 | Case report | 1 | Vaccine escape | G145R, P120Q, I126T |
| Seddighi-Tonekaboni et al. [80] | United Kingdom | 4 | Cross-sectional | 2 | Vaccine escape | G145A, T126I |
| Ngu et al. [81] | England, Wales | 17 | Cross-sectional | 2 (12) | Vaccine escape | P120Q, F134Y, D144A, I126N |
| Carman et al. [82] | Multinational | 32 | Cross-sectional | 1 | Vaccine escape | G145R |
| Laoi et al. [78] | Ireland | 32 | Cross-sectional | 6 (18.5) | Vaccine escape, detection failure | G145A, F134L, D144E, S143L |
| Foy et al. [87] | United States | 1 | Case report | 1 | Immune escape | D144E |

HBsAg: Hepatitis B surface antigen.
Table 3  Clinical significance of hepatitis B surface antigen mutations in chronic hepatitis B

| Ref.            | Country         | No. of patients | Type of study | Patients with HBsAg mutation, n (%) | Clinical significance                                                                 |
|-----------------|-----------------|-----------------|---------------|-------------------------------------|--------------------------------------------------------------------------------------|
| Abe et al [65]  | Japan           | 40              | Case-control  | 27/50 (90) in HCC+ 0/10 (0) in HCC- | Correlation between pre-S deletion and HCC (P < 0.001)                               |
| Blackberg et al [33] | Sweden       | 35              | Case-control  | 8/16 (50) in HCC+ 4/19 (21) in HCC- | No correlation between Pre-S2 mutations and HCC (P > 0.05)                             |
| Cao et al [66]  | China           | 97              | Case-control  | 34/47 (72.3) in HCC+ 13/50 (26) in HCC- | Correlation between pre-S deletion or pre-S2 start codon mutation and HCC (P < 0.001) |
| Chen et al [67] | Taiwan          | 152             | Cross-sectional | 26/50 (52.0) in HCC- 30/102 (29.4) in HCC- | Correlation between pre-S deletion and HCC (P < 0.001)                                |
| Chen et al [68] | Taiwan          | 240             | Case-control  | Pre-S deletion: 28/80 (35) in HCC+ vs 27/160 (16.9) in HCC- | Correlation between pre-S deletion or pre-S2 start codon mutation and HCC (P < 0.001) |
| Choi et al [69] | South Korea     | 300             | Cross-sectional | W4P/R: 10/80 (12.5) in HCC+ vs 7/160 (4.4) in HCC- M1V/Y1/A: 25/80 (28.8) in HCC+ vs 24/160 (15) in HCC- | Correlation between pre-S deletion or pre-S2 start codon mutation and HCC (P < 0.001) |
| Fang et al [70] | China           | 66              | Case-control  | 51/228 (22.4) in HCC- 15/53 (45.5) in HCC+ | Correlation between pre-S deletion and HCC (P < 0.01)                                 |
| Gao et al [71]  | China           | 79              | Cross-sectional | 6/33 (18.2) in HCC- 10/26 (38.5) in HCC+ | Correlation between pre-S deletion and HCC (P < 0.001)                                |
| Huang et al [72] | Taiwan          | 38              | Case-control  | 3/55 (5.7) in HCC- 9/19 (47.4) in HCC+ | Correlation between pre-S deletion and HCC (P < 0.008)                                |
| Hung et al [73] | Taiwan          | 313             | Cross-sectional | 1/19 (5.3) in HCC- 41/146 (40) in HCC- | Correlation between pre-S deletion and HCC (P < 0.001)                                |
| Huy et al [74]  | 12 countries    | 352             | Cross-sectional | 5/167 (3.0) in HCC- 17/49 (34.7) in HCC+ 50/303 (16.5) in HCC- | Correlation between pre-S1 deletion and pre-S2 start codon mutations and HCC (P < 0.05) |
| Jang et al [75] | South Korea     | 119             | Cross-sectional | 17/48 (35.4) in HCC+ 13/71 (18.3) in HCC+ | Correlation between pre-S deletion and HCC (P < 0.05)                                |
| Kao et al [76]  | Taiwan          | 168             | Case-control  | 56/112 (50.0) in HCC+ 4/56 (7.1) in HCC+ 28/135 (18.5) in HCC+ 6/135 (4.4) in HCC- | Correlation between pre-S deletion and HCC (P < 0.001)                                |
| Lee et al [77]  | South Korea     | 270             | Case-control  | 19/153 (12.4) in advanced liver disease (LC or HCC) 1/94 (1.1) in non-advanced liver disease | Correlation between W4P/R mutation and HCC or cirrhosis (P < 0.05)                   |
| Lin et al [78]  | Taiwan          | 266             | Cross-sectional | 19/64 (29.7) in HCC+ 25/202 (12.4) in HCC- | Correlation between pre-S deletion and HCC (P = 0.02)                                 |
| Mun et al [79]  | South Korea     | 120             | Cross-sectional | Pre-S1: 13/40 (32.5) in HCC+ vs 11/80 (13.7) in HCC- | Correlation between pre-S1 (P = 0.027) and pre-S1 start codon mutations (P = 0.048) and HCC. Correlation between pre-S2 deletions and cirrhosis (P < 0.001) |
| Qu et al [80]   | China           | 193             | Case-control  | Pre-S deletion: 28/96 (29.2) vs 11/97 (11.3), Pre-S2 start codon: 17/96 (17.7) vs 7/97 (7.2), T31C: 23/96 (24.0) vs 37/97 (38.1), T35C: 56/96 (37.5) vs 23/97 (23.7), T766A: 13/96 (13.5) vs 14/97 (14.4) in HCC- vs LC- vs 4/59 (6.8) in LC- | Correlation between pre-S deletion (P = 0.003), pre-S2 start codon mutation (P = 0.027), T31C (P = 0.044), T53C (P = 0.027) but not T766A mutation (P = 0.966) and HCC. |
| Raimondo et al [81] | Italy         | 110             | Cross-sectional | 16/19 (84.2) in HCC- 40/91 (43.9) in HCC- 13/24 (54.2) in HCC+ 31/171 (18.1) in HCC- | Correlation between pre-S2 deletion or start codon mutation and HCC (P < 0.02)        |
| Sinn et al [82] | South Korea     | 195             | Cohort        | 20/58 (34.5) in advanced liver disease (LC or HCC) 17/102 (16.7) in non-advanced liver disease | Correlation between pre-S deletion and HCC or cirrhosis (P < 0.05)                   |
| Sugauchi et al [83] | Japan          | 160             | Cross-sectional | T31C: 6/16 (37.5) in HCC+ vs 0/10 (0.0) in HCC- T35C: 6/16 (37.5) in HCC+ vs 1/10 (10.0) in HCC- 24/65 (36.9) in HCC+ 34/89 (38.2) in HCC- 28/96 (29.2) in HCC+ 4/96 (14.6) in HCC+ 74/157 (47.1) in HCC+ 45/160 (28.1) in HCC- | Correlation between pre-S3 and T53C mutations and HCC (P < 0.05)                     |
| Sung et al [84] | Hong Kong       | 26              | Case-control  | T31C: 6/16 (37.5) in HCC+ vs 0/10 (0.0) in HCC- | No correlation between pre-S1/S2/S deletion or start codon mutation and HCC (P = 0.015) |
| Thongbai et al [85] | Thailand      | 154             | Cross-sectional | 34/89 (38.2) in HCC- 28/96 (29.2) in HCC+ 4/96 (14.6) in HCC+ 74/157 (47.1) in HCC+ 45/160 (28.1) in HCC- | No correlation between pre-S1/S2/S deletion or start codon mutation and HCC (P = 0.015) |
| Yeung et al [86] | Taiwan          | 192             | Case-control  | 14/96 (14.6) in HCC+ 74/157 (47.1) in HCC+ 45/160 (28.1) in HCC- | Correlation between pre-S deletion and HCC (P < 0.001)                                |
| Zhao et al [87] | China           | 317             | Case-control  | Pre-S deletion: 9/40 (22.5) in HCC- 37/97 (38.1), T53C: 36/96 (37.5) in HCC+ vs 17/49 (34.7) in HCC+ 50/303 (16.5) in HCC- | Correlation between pre-S deletion or pre-S2 start codon mutations and HCC (P < 0.001) |

Correlation between T31C and T53C mutations (P < 0.05) and M1V/I/A mutations (P < 0.001) and HCC (P < 0.001).
tested positive for pre-S mutations. Two subsequent Chinese case-control studies on 317 and 193 HBsAg-positive patients, respectively, identified pre-S deletions\cite{101,102} and pre-S2 start codon mutations\cite{102} as independent predictors of HCC development. Abe et al\cite{103} found a correlation between the presence of pre-S1 or pre-S2 deletions and the occurrence of HCC in a case-control study on 40 Asian children with chronic HBV infection, a finding confirmed in a retrospective study on 38 Taiwanese children\cite{104} in which the presence of pre-S2 mutations was identified as an independent predictor of HCC development.

Instead, a cross-sectional study\cite{105} enrolling 154 patients from Thailand failed to show an association between HCC and pre-S1 or pre-S2 deletions or start codon mutations. Likewise, a small case-control study showed no association between pre-S2 mutations and HCC in 35 patients from different countries\cite{106}.

The S region of the HBV genome may present point mutations that could alter HBsAg secretion. These point mutations were investigated by some Authors to identify a possible correlation between their presence and the development of HCC. Chen et al\cite{95} found a correlation between the W4P/R mutation and the occurrence of HCC, an observation endorsed by the data from a cross-sectional study from South Korea\cite{107} on 247 HBsAg-positive patients in which the prevalence of W4P/R mutants was higher in patients with cirrhosis or HCC than in those with a less severe liver illness. In addition, Qu et al\cite{108} in a larger study confirmed the association of the T31C and T53C mutations with the occurrence of HCC previously demonstrated in a small cohort study\cite{108} published in 2008. In Qu's study the T766A mutant and HCC were not associated, whereas a case-control study carried out by Zhu et al\cite{109} on 55 HBV-infected Chinese patients showed a significant association between the pre-S2 start codon (P = 0.014), T53C (P = 0.004) and T766A (P = 0.043) mutations and the occurrence of HCC.

**CONCLUSION**

The association of single or multiple aa substitutions in the HBsAg region with failed protection in infants who received passive/active prophylaxis and in HBsAg-positive liver transplant patients undergoing continuous passive immunoprophylaxis should alert clinicians to the possible onset of acute hepatitis B or a reactivation of a previous HBV infection, respectively, in these cases.

Similarly, the possibility that some subjects resulting HBsAg-negative may harbor HBV infection because an aa substitution has made the presence of HBsAg undetectable with the commercially available assays should be taken into account by clinicians and healthcare personnel working in laboratories and blood banks.

Although several studies reported an association between HBsAg mutations and HCC, the data on this point are not conclusive because most of the studies were performed in south-eastern Asia, some of them were very small, most of them were cross-sectional and a few reported data contrasting with those from the majority of studies. A large worldwide study, planned on the basis of the data available, would almost certainly improve our knowledge on this topic.

**REFERENCES**

1. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. *J Clin Virol* 2005; 34 Suppl 1: S1-S3 [PMID: 16612108 DOI: 10.1016/S1386-6532(05)00384-7]

2. Sagnelli E, Stroffolini T, Mele A, Imparato M, Sagnelli C, Coppola N, Almasio PL. Impact of comorbidities on the severity of chronic hepatitis B at presentation. *World J Gastroenterol* 2012; 18: 1616-1621 [PMID: 22529690 DOI: 10.3748/wjg.v18.i16.1616]

3. Sagnelli E, Stroffolini T, Mele A, Imparato M, Almasio PL. Chronic hepatitis B in Italy: new features of an old disease—approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. *Clin Infect Dis* 2008; 46: 110-113 [PMID: 18171224 DOI: 10.1086/524074]

4. Coppola N, Corvino AR, De Pascalis S, Signoriello G, Di Fiore E, Nienhaus A, Sagnelli E, Lambert M. The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy. *BMC Infect Dis* 2015; 15: 149 [PMID: 25884719 DOI: 10.1186/s12879-015-0874-3]

5. Borgia G. Gentile I. Treating chronic hepatitis B: today and tomorrow. *Curr Med Chem* 2006; 13: 2839-2855 [PMID: 17073632 DOI: 10.2174/092986706778521995]

6. Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. *World J Gastroenterol* 2009; 15: 5761-5769 [PMID: 19998495]

7. Arauz-Ruiz P, Norder H, Robertson BH, Magnus LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. *J Gen Virol* 2002; 83: 2059-2073 [PMID: 12124470]

8. Tran TT, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. *J Virol* 2008; 82: 5657-5663 [PMID: 18353958 DOI: 10.1128/jvi.02556-07]

9. Olinger CM, Jutavijittum P, Hübschen JM, Yousukh A, Samounty B, Thammavong T, Toriyama K, Muller CP. Possible new hepatitis B virus genotype, southeast Asia. *Emerg Infect Dis* 2008; 14: 1777-1780 [PMID: 18976569 DOI: 10.3201/eid1411.080437]

10. Yu H, Yuan Q, Ge SX, Wang HY, Zhang YL, Chen QR, Zhang J, Chen PJ, Xia NS. Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype \( \text{"} \cdot \text{"} \). *PLoS One* 2010; 5: e9297 [PMID: 20174575 DOI: 10.1371/journal.pone.0009297]

11. Zehender G, Ebranati E, Gabanelli E, Sorrentino C, Lo Presti A, Tanzi E, Ciccozzi M, Galli M. Enigmatic origin of hepatitis B virus: an ancient travelling companion or a recent encounter? *World J Gastroenterol* 2014; 20: 7622-7634 [PMID: 24976700 DOI: 10.3748/wjg.v20.i24.7622]
Coppola N et al. HBsAg mutants

human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009; 83: 10538-10547 [PMID: 19640977 DOI: 10.1128/JVI.00462-09]

13 Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol 2014; 20: 7655-7663 [PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635]

14 Ganem D, Schneider R. Hepadnaviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia: Lippincott-Raven, 2001: 2923-2970

15 Sagnelli C, Ciccozzi M, Pisaturo M, Lo Presti A, Cella E, Coppola N, Sagnelli E. The impact of viral molecular diversity on the clinical presentation and outcome of acute hepatitis B in Italy. New Microbiol 2015; 38: 137-147 [PMID: 25915056]

16 Coppola N, Tonziello G, Colomboatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B J Infect 2013; 67: 322-328 [PMID: 23796869]

17 Coppola N, Sagnelli C, Pisaturo M, Minichini C, Messina V, Alessio L, Starace M, Signoriello G, Gentile I, Filippini P, Sagnelli E. Clinical and virological characteristics associated with severe acute hepatitis B. Clin Microbiol Infect 2014; 20: 0991-0997 [PMID: 24930916 DOI: 10.1111/cmi.121720]

18 Harrison T. Desk Encyclopedia of General Virology. Boston: Academic Press, 2009: 455

19 Howard CR. The biology of hepatitis viruses. J Gen Virol 1986; 67 (Pt 7): 1215-1235 [PMID: 3014045 DOI: 10.1099/0002-1377-67-7-1215]

20 Schaefer S. Hepatitis B virus genotypes in Europe. Hepatol Res 2007; 35: S20-S26 [PMID: 17627630 DOI: 10.1111/j.1872-0232.2007.00099.x]

21 He B, Fan Q, Yang F, Hu T, Qiu W, Feng Y, Li Z, Li Y, Zhang F, Guo H, Zou X, Tu C. Hepatitis virus in long-fingered bats, Myanmar. Emerg Infect Dis 2013; 19: 638-640 [PMID: 23631923 DOI: 10.3201/eid1904.121655]

22 Coppola N, Loquercio G, Tonziello G, Azzaro R, Pisaturo M, Di Costanzo G, Starace M, Pasquale G, Cacciapuoti C, Petruzziello B. HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol 2015; 58: 315-317 [PMID: 23856167 DOI: 10.1016/j.jcv.2013.06.020]

23 Mirabella C, Surdo M, Van Hemert F, Lian Z, Salpini R, Cento V, Cortese MF, Arraghi A, Pollicino T, Alberi A, Bertoli AR, Berkhout B, Michel V, Gubertini G, Servant-Delmas A, Bagot S, Zanus S, MGH Colombo M. Hepatitis B virus infection result in decreased surface antigen expression in vitro. J Viral Hepat 2012; 19: 716-723 [PMID: 22967103 DOI: 10.1111/j.1365-3328.2012.01595.x]

24 Martin CM, Welge JA, Rouster SD, Shata SM, Sherman KE, Biehl JD, Dussaux E, Laplace S, Roque-Afonso AM. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 2006; 44: 2321-2326 [PMID: 16825343 DOI: 10.1128/JCM.00121-06]

25 Hou J, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, Zhou F, Waters J, Karayannis P, Luo K. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 2001; 34: 1027-1034 [PMID: 11679975 DOI: 10.1053/jhep.2001.28708]

26 Yao QQ, Dong XL, Wang XC, Ge SX, Hu AQ, Liu HY, Wang YA, Yuan Q, Zheng YJ. Hepatitis B virus surface antigen (HBsAg)-positive and HBsAg-negative hepatitis B virus infection among mother-teenager pairs 13 years after neonatal hepatitis B virus vaccination. Clin Vaccine Immunol 2013; 20: 269-275 [PMID: 23254296 DOI: 10.1128/CVI.00539-12]

27 Yong-Lin Y, Qiang F, Ming-Shun Z, He C, Gui-Ming M, Zu-Hu H, Xue-Xiang C. Hepatitis B surface antigen variants in voluntary blood donors in Nanjing, China. Virol J 2012; 9: 82 [PMID: 22505577 DOI: 10.1186/1743-422X-9-82]

28 Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007; 45: 277-285 [PMID: 17256766 DOI: 10.1002/hep.21529]

29 Abdelnabi Z, Saleh N, Baraghithi S, Glebe D, Azim M. Subgenotypes and mutations in the s and polymerase genes of hepatitis B virus carriers in the West Bank, palestine. PLoS One 2014; 9: e113821 [PMID: 25503289 DOI: 10.1371/journal.pone.0113821]

30 Darmawan E, Turyadi KE, Nursanty NK, Tedha MD, Muljono DH. Seroenepidemiology and occult hepatitis B virus infection in young adults in Banjarmasin, Indonesia. J Med Virol 2015; 87: 199-207 [PMID: 25521058 DOI: 10.1002/jmv.24045]

31 Romanò L, Paladini S, Galli C, Raimondo G, Pollicino T, Zanetti AR. Hepatitis B vaccine. Hum Vaccin Immunother 2015; 11: 53-57 [PMID: 25483515 DOI: 10.4161/hv.34306]

32 Thakur V, Kazim SN, Gunpat RA, Hasnain SE, Bartholomeusz A, Malhotra V, Sarin SK. Transmission of G145R mutant of HBV to an unrelated contact. J Med Virol 2005; 76: 40-46 [PMID: 15778957 DOI: 10.1002/jmv.20321]

33 Norouzi M, Hgorashi S, Abedi F, Nejatizadeh A, Ataei B, Malekzadell S, Alavian S, Judaki M, Ghamari S, Namazi A, Rahimnia R, Khedive A, Jazeh S, Ismail AR. Identification of Hepatitis B Virus Surface Antigen (HBsAg) Genotypes and Variations in Chronic Carriers from Isfahan Province, Iran. Iran J Public Health 2012; 41: 104-111 [PMID: 23131354]

34 Komatsu H, Inui A, Sogo T, Konishi Y, Tateno A, Fujisawa T. Hepatitis B surface gene 145 mutant as a minor population in hepatitis B virus carriers. BMC Res Notes 2012; 5: 22 [PMID: 22233650 DOI: 10.1186/1756-0500-5-22]

35 Mele A, Tancredi F, Romano L, Giuseppeppone A, Colucci M, Sangiulio A, Lecce R, Adamo B, Tosti ME, Taliani G, Zenatti AR. Effectiveness of hepatitis B vaccination in babies born to hepatitis B virus-positive mothers in Italy. J Infect Dis 2001; 184: 905-908 [PMID: 11509998 DOI: 10.1086/323396]

36 Torresi J, Kameyama-Fujii L, Bledsky A, Edgerton A, Kuzhan H, Locarnini SA, Fyle J, Sozzi T, Jackson DC. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virolology 2002; 293: 305-313 [PMID: 11886250 DOI: 10.1006/jviro.2001.1246]

37 Zuckerman JN, Zuckerman AJ. Mutations of the surface protein of hepatitis B virus. Antiviral Res 2003; 60: 75-78 [PMID: 14638401 DOI: 10.1016/j.antiviral.2003.08.013]

38 Margeridon-Thermet S, Shluman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Bahzadheh F, Gharizadeh B, Hanczaruk B, Sinen BB, Egholm M, Shafer RW. Ultra-deep pyrosequencing
of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 2009; 199: 1275-1285 [PMID: 1903060;10.1086/597808]

43 Araujo NM, Vianna CO, Moraes MT, Gomes SA. Expression of Hepatitis B virus surface antigen (HBsAg) from genotypes A, D and F and influence of amino acid variations related to not to genotypes on HBsAg detection. Braz J Infect Dis 2009; 13: 266-271 [PMID: 20231988 DOI: 10.1590/S1413-86702009000400005]

44 Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyn J, Fraune M, Garcia A, Phillips RO. Detection of highly prevalent hepatitis B virus coinfection among HIV-coinfected persons in Ghana. J Clin Microbiol 2010; 48: 3223-3230 [PMID: 20631103 DOI: 10.1128/JCM.02321-09]

45 Dunford L, Carr MJ, Dean J, Nguyen LT, Ta Thi TH, Nguyen BT, Connell J, Coughlan S, Nguyen HT, Hall WW, Thi LA. A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. PLoS One 2012; 7: e39027 DOI: 10.1371/journal.pone.0039027

46 Kuzin SN, Zabolitina EE, Zabelin NN, Kudriavtseva EN, Zuckerman AJ, Thomas HC. Hepatitis B virus genotypes and HBV-DNA mutations in plasma and sera of patients with chronic hepatitis B infection in Russia. Zh Mikrobiol Epidemiol Immunobiol 2012; (1): 68-75 [PMID: 22442974]

47 Lin YM, Jou GM, Mu SC, Chen BF. Naturally occurring hepatitis B virus B cell and T cell epitope mutations in hepatitis B vaccinated children. ScientificWorldJournal 2013; 2013: 571875 [PMID: 24379746 DOI: 10.1155/2013/571875]

48 Bian T, Yan H, Shen L, Wang F, Zhang S, Cao Y, Zhang S, Zhang Y, Bi S. Change in hepatitis B surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China. J Virol 2013; 87: 12196-12206 [PMID: 24006443 DOI: 10.1128/JVI.02127-13]

49 Magiorkinis E, Paraskevis D, Pavlopoulou ID, Kantzanou M, Haidt C, Hatzakis A, Boletis IN. Renal transplantation from hepatitis B surface antigen (HBsAg)-positive donors to HBsAg-negative recipients: a case of post-transplant fulminant hepatitis associated with an extensively mutated hepatitis B virus genome and review of the current literature. Transplant Infect Dis 2013; 15: 393-399 [PMID: 23775851 DOI: 10.1111/tid.12094]

50 Servant-Delmas A, Mercier-Darty M, Ly TD, Wind F, Allouci C, Sureau C, Lapereche S. Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg variants in blood samples. J Clin Virol 2012; 53: 338-345 [PMID: 22926790 DOI: 10.1016/j.jcv.2012.01.003]

51 Wu C, Shi H, Wang Y, Lu M, Xu Y, Chen X. A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy. Viral Sin 2012; 27: 369-372 [PMID: 23180290 DOI: 10.1007/s12250-012-3284-3]

52 Salpini R, Colagrossi L, Bellocci MC, Surdo M, Becker C, Alteri C, Aragri M, Ricciardi A, Armenia D, Pollicita M, Di Santo F, Caristi L, Louzoun Y, Mastroiani CM, Lichtner M, Paoloni M, Esposito M, D’Amore C, Marrone A, Marignani M, Sarracchia C, Sarmati L, Andreoni M, Angelico M, Verheyn J, Perno CF, Schildrath J, Coppola N et al. HBsAg mutants

53 Bahramali G, Sadeghizadeh M, Amini-Bavil-Olyaee S, Alavain SM, Bekrad-Bahbahani A, Adeli A, Aghasagheghi MR, Amini S, Mahboudi F. Clinical, virologic and phylogenetic features of hepatitis B infection in Iranian patients. World J Gastroenterol 2008; 14: 5448-5453 [PMID: 18803358 DOI: 10.3748/wjg.14.5448]

54 Channani N, Louisirotcheranakul S, Oota S, Sakuldamrongpanich T, Saldanha J, Chongkolwatana V, Phikulsod S. Genetic characterization and genotyping of hepatitis B virus (HBV) isolates from donors with an occult HBV infection. Vox Sang 2014; 107: 324-332 [PMID: 25040474 DOI: 10.1111/vox.12178]
Pan, M, Raychoudhury S, Panda MK. Prevalence of hepatitis B surface antigen in the healthy population of India: a prospective study in 176 restaurant employees. J Gastroenterol Hepatol 2001; 16: 867-71 [PMID: 11602677 DOI: 10.1046/j.1349-7006.2001.00839.x]

84 Li PW, Zhang L, Gao J, Zhang QL, Wang H, Wang PS, Wang Y. Association of chronic hepatitis B with the development of multiple primary malignancies. J Hepatol 2011; 55: 267-73 [PMID: 21363343 DOI: 10.1016/j.jhep.2011.03.019]

85 Wang JC, Lu SN. Combined mutations in pre-s/surface and core regions of hepatitis B virus increase the risk of hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 1563-9 [PMID: 17350581 DOI: 10.1111/j.1440-1746.2007.04602.x]

86 Wang H, Lai MD, Su IJ. Prevalence and significance of hepatitis B virus infection in a university population in Taiwan. J Med Virol 2004; 73: 296-302 [PMID: 15213368 DOI: 10.1002/jmv.20382]

87 Raimondo G, Costantin L, Caccamo G, Pollicino T, Squadrini G, Cacioppo L, Banicotti C. Non-invasive assessment procedure for the determination of hepatitis B viral load and its association with clinical parameters. J Med Virol 2004; 74: 5-11 [PMID: 15126360 DOI: 10.1002/jmv.20296]
Zhao ZM, Jin Y, Gan Y, Zhu Y, Chen TY, Wang JB, Sun Y, Cao ZG, Qian GS, Tu H. Novel approach to identifying the hepatitis B virus pre-S deletions associated with hepatocellular carcinoma. *World J Gastroenterol* 2014; 20: 13573-13581 [PMID: 25309088 DOI: 10.3748/wjg.v20.i37.13573]

Qu LS, Liu JX, Liu TT, Shen XZ, Chen TY, Ni ZP, Lu CH. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. *PLoS One* 2014; 9: e98257 [PMID: 24849936 DOI: 10.1371/journal.pone.0098257]

Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, Inma A, Jang JJ, Su JI. Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. *Cancer Sci* 2009; 100: 2249-2254 [PMID: 19719772 DOI: 10.1111/j.1349-7006.2009.01309.x]

Huang HP, Hsu HY, Chen CL, Ni YH, Wang HY, Tsuei DJ, Chiang CL, Tsai YC, Chen HL, Chang MH. Pre-S2 deletions of hepatitis B virus and hepatocellular carcinoma in children. *Pediatr Res* 2010; 67: 90-94 [PMID: 19816238 DOI: 10.1203/PDR.0b013e3181c1b6b7]

Thongbai C, Sa-nguanmoo P, Kranokpiruk P, Poovorawan K, Poovorawan Y, Tangkijvichian P. Hepatitis B virus genetic variation and TP53 R249S mutation in patients with hepatocellular carcinoma in Thailand. *Asian Pac J Cancer Prev* 2013; 14: 3555-3559 [PMID: 23886144 DOI: 10.7314/APJCP.2013.14.6.3555 DOI: 10.1159/000350738]

Blackberg J, Kidd-Ljunggren K. Mutations within the hepatitis B virus genome among chronic hepatitis B patients with hepatocellular carcinoma. *J Med Virol* 2003; 71: 18-23 [PMID: 12858404 DOI: 10.1002/jmv.10458]

Lee SA, Kim KJ, Kim DW, Kim BI. Male-specific W4P/R mutation in the pre-S1 region of hepatitis B virus, increasing the risk of progression of liver diseases in chronic patients. *J Clin Microbiol* 2013; 51: 3928-3936 [PMID: 24025913 DOI: 10.1128/JCM.01505-13]

Sung JJ, Tsui SK, Tse CH, Ng EY, Leung KS, Lee KH, Mok TS, Bartholomeusz A, Au TC, Tsoi KK, Locarnini S, Chan HL. Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. *J Virol* 2008; 82: 3604-3611 [PMID: 18216102 DOI: 10.1128/JVI.01197-07]

Zhu Y, Jin Y, Guo X, Bai X, Chen T, Wang J, Qian G, Groopman JD, Gu J, Li J, Tu H. Comparison study on the complete sequence of hepatitis B virus identifies new mutations in core gene associated with hepatocellular carcinoma. *Cancer Epidemiol Biomarkers Prev* 2010; 19: 2623-2630 [PMID: 20699378 DOI: 10.1159/000350738 DOI: 10.1159/000350738]

Hung CH, Chen CH, Lee CM, Hu TH, Lu SN, Wang JH, Huang CM. Role of viral genotypes and hepatitis B viral mutants in the risk of hepatocellular carcinoma associated with hepatitis B and C dual infection. *Intervirology* 2013; 56: 316-324 [PMID: 23838434 DOI: 10.1159/000350738]
